Baby's first steps after world-first CRISPR gene therapy at home

A year ago, KJ Muldoon's doctors weren't sure he'd survive infancy. Today, he's taking his first steps at home with his family—a milestone that seemed impossible before a medical breakthrough changed everything.

Earlier this year, physicians at Children's Hospital of Philadelphia treated KJ with a one-of-a-kind CRISPR gene-editing therapy tailored specifically for him. The personalized treatment targeted a rare metabolic disorder that typically proves fatal in babies. KJ became the first person in the world to receive this type of customized genetic edit, and the results have been striking. After spending most of his first ten months in hospital care, he was discharged in June and has been hitting developmental milestones ever since.

What makes this story matter beyond the medical record: KJ's therapy didn't just extend his life—it fundamentally changed what his life could look like. His parents brought him home. He celebrated his first birthday outside hospital walls in August. This month, he'll spend Christmas with his family in their own house, not a hospital room. These aren't small things when you've spent a year watching your baby in an intensive care unit.

From survival to childhood

Dr. Rebecca Ahrens-Nicklas, who leads the Gene Therapy for Inherited Metabolic Disorders program at CHOP, and her collaborator Dr. Kiran Musunuru at the University of Pennsylvania are already thinking beyond KJ's case. They're studying how to adapt the approach for other children facing similar rare metabolic disorders—urea cycle disorders, organic acidemias, fatty acid oxidation disorders. Each one presents different genetic puzzles, but the principle is the same: if you can edit the gene causing the problem, you might be able to stop the disease before it takes hold.

Laboratory teams now use KJ's response as a reference point. His case offers crucial data on dosing, safety, and what long-term monitoring looks like for patients who receive personalized gene therapy.

There's also a regulatory shift happening quietly in the background. KJ's treatment challenged the traditional drug approval model—it wasn't a large trial, just one patient with one custom-designed therapy. A recent editorial in the New England Journal of Medicine highlighted his case as a turning point for how regulators and researchers think about rare diseases. When you're treating something that affects maybe a handful of children worldwide, the old playbook doesn't fit.

For families facing rare metabolic diseases, KJ's progress offers something more grounded than hype: evidence that rapid collaboration between clinicians, researchers, and regulators can actually change outcomes. His growing list of first moments—first steps, first birthday at home, first Christmas with family—shows what that shift looks like in practice.